Energy Premium Extends Lifeline: Algeria Eases Budget Pressure Amid Middle East Conflict

On October 8, shares of heart disease drug developer Atrium Therapeutics (RNA.O) rose 11.3% to $8.83 in pre-market trading on Thursday after the company successfully raised $50 million. The biopharmaceutical company announced it has agreed to sell about 6.3 million shares and pre-funded warrants to institutional investors through a private placement at $7.93 per share. RNA’s shares closed down 0.8% at $7.93 on Wednesday and have fallen roughly 44% in the past month. The company plans to use the net proceeds for the development of its two main product candidates, other research projects, among other uses. Atrium expects that the funds raised, together with existing cash and investments, will be sufficient to support its operations through 2028. Leerink acted as the lead placement agent for this offering, with Cantor Fitzgerald, Barclays, and Wells Fargo participating as well. Based in San Diego, California, Atrium has signed collaboration agreements with Bristol Myers Squibb (BMY.N) and Eli Lilly (LLY.N), and has about 17.1 million shares outstanding. Atrium began public trading on February 27 (link), following a spinoff from Avidity Biosciences (link), which was subsequently acquired by Swiss pharmaceutical company Novartis (NOVN.S).

October 8 - ** Shares of dental products distributor Henry Schein (HSIC.O) dropped 2% to $82 in pre-market trading. ** Ronald South, who has served as CFO for the past four years, will transition to Senior Advisor. ** Emmanuel Caprais will take over as CFO, officially assuming the role on November 4. ** Caprais was previously the Chief Financial Officer of global industrial manufacturer ITT. ** This leadership change comes about seven months after Frederick Lowery succeeded Stanley Bergman as CEO; Bergman had led the company for 35 years. ** Among 18 brokers, 9 rate the stock as “buy” or above, 8 as “hold”, and 1 as “sell”; the median target price is $96—data compiled by LSEG. ** As of the previous trading day's close, the stock has risen 10.69% year-to-date.

07:34 AM EDT, 10/08/2026 (MT Newswires) -- Movado (MOV) said Thursday that it has agreed to sell a 95% stake in its EBEL luxury watch brand for $66.5 million to a group led by Montres Journe, with participation from Chanel and Pierre Jacques. The deal enables Movado to deepen its focus on its core luxury and fashion watch and jewelry products, it said. Movado said it will initially transfer EBEL's intellectual property, inventory, and certain other assets to a newly formed Swiss unit, while retaining a 5% stake in the business. The transaction, expected to close in the next few months, is subject to adjustments and closing conditions, the company said.

Hydreight Technologies disclosed a C$ 300,000 minority investment in Insu Therapeutics, completed on March 13, 2026. The deal also granted Hydreight U.S. distribution rights for peptide medicines using Insu’s buccal delivery technology, subject to development success. Insu received a USPTO Notice of Allowance on a buccal peptide-delivery patent application, reinforcing Hydreight’s strategic stake. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hydreight Technologies Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202610080730CANADANWCANADAPR_C0229) on October 08, 2026, and is solely responsible for the information contained therein.